Heska Corp (HSKA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

3760 ROCKY MOUNTAIN AVENUE LOVELAND, CO 80538

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. It operates in two segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes diagnostic instruments and supplies, as well as single use diagnostic and other tests, vaccines and pharmaceuticals, primarily for canine and feline use. These products are sold directly by the Company as well as through independent third-party distributors and through other distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals and fish. In February 2013, it announced the acquisition of 54.6% interest of Cuattro Veterinary USA, LLC.

Data as of 2021-01-16
Market Cap1.516 Billion Shares Outstanding9.455 Million Avg 30-day Volume76.461 Thousand
P/E Ratio-72.8 Dividend Yield EPS-2.22
Price/Sales11.398 Price cash flow ratio159.9 Price free cash flow ratio-11.9
Book Value29.07 Price to Tangible Book11.38 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.269276
BETA1.64483 52-week High/Low163.63 / 50.0 Stddev0.139478
View SEC Filings from HSKA instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 2 -50.0% 1 (0.07%) 2 (0.13%) -50.0%
Funds Holding: 125 127 -1.57% 28 (1.84%) 27 (1.75%) 3.7%
13F shares: 9.081 Million 9.08 Million 0.01% 3.674 Million 3.943 Million -6.82%
% Ownership 96.1569 96.6793 -0.54% 38.9084 41.988 -7.33%
New Positions: 10 20 -50.0% 4 7 -42.86%
Increased Positions 54 58 -6.9% 11 11 0.0%
Closed Positions 10 13 -23.08% 2 6 -66.67%
Reduced Positions 40 28 42.86% 10 6 66.67%
Total Calls 0
Total Puts 2.88 Thousand 0
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding HSKA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HSKA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

14.3 Thousand total shares from 7 transactions

Exercise Derivative Conversion (M)

30.6 Thousand total shares from 5 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WILSON KEVIN S. CEO AND PRESIDENT

  • Officer
  • Director
396,333 2021-01-14 12

HASENMAIER JOACHIM A.

  • Director
0 2021-01-11 2

WISNEWSKI NANCY CHIEF OPERATING OFFICER

  • Officer
51,874 2020-12-28 7

AROESTY JASON D EVP, INTERNATIONAL DIAGNOSTICS

  • Officer
0 2020-11-27 1

ANTIN ROBERT L

  • Director
420 2020-11-17 2

TROWBRIDGE BONNIE J.

  • Director
4,089 2020-11-09 2

SVEEN CHRISTOPHER D. CAO & GENERAL COUNSEL

  • Officer
948 2020-09-24 3

BAKER ELEANOR F. EVP, MANAGING DIR. & COO, SCIL

  • Officer
883 2020-09-24 3

DAVIS STEPHEN L

  • Director
1,284 2020-08-20 2

GRASSMAN CATHERINE EVP, CFO

  • Officer
3,723 2020-06-01 3

EYL STEVEN M. EVP, CCO & PRES.SCIL

  • Officer
0 2020-04-16 2

LARSON SHARON J.

  • Director
6,839 2020-04-08 1

SVEEN DAVID E.

  • Director
32,741 2020-04-08 1

HUMPHREY SCOTT

  • Director
5,112 2020-04-08 1

FURLONG MARK F

  • Director
2,957 2020-04-08 1

NAPOLITANO JASON A CHIEF STRATEGY OFFICER

  • Officer
62,799 2019-12-30 0

GORDON G IRWIN

  • Director
25,074 2018-11-29 0

LIPPINCOTT ROD EVP, COMP. ANIMAL HEALTH SALES

  • Officer
8,573 2018-08-31 0

ASAKOWICZ STEVE EVP, COMP. ANIMAL HEALTH SALES

  • Officer
8,400 2018-08-27 0

WRENN CAROL

  • Director
5,249 2018-05-03 0

MCGINLEY MICHAEL J PRESI, BIOLOGIC. & PHARM.

  • Officer
86,776 2018-03-17 0

MCMAHON JOHN VP, CHIEF FINANCIAL OFFICER

  • Officer
68 2017-08-30 0

GRIEVE ROBERT B EXECUTIVE CHAIR

  • Officer
  • Director
106,331 2015-08-28 0

AYLESWORTH WILLIAM A

  • Director
37,397 2015-03-09 0

BENT MICHAEL A V.P.ACTG. OFFICER & CONTROLLER

  • Officer
9,773 2012-12-28 0

ZACHARA CLAUDINE

  • VP, MARKETING
0 2012-12-19 0

APERFINE JOSEPH EVP, SALES AND MARKETING

  • Officer
0 2012-12-19 0

CMC MASTER FUND, L.P.

CMC MASTER FUND PARTNERS, LLC

  • 10% Owner
No longer subject to file 2012-10-09 0

EIO PETER

  • Director
0 2012-05-08 0

SASEN JOHN F

  • Director
0 2012-05-08 0

MCCORMICK LOUISE L.

  • Director
0 2012-05-08 0

CMC MASTER FUND, L.P.

CMC MASTER FUND PARTNERS, LLC

C.M. CAPITAL ADVISORS, LLC

C.M. CAPITAL CORP

  • 10% Owner
579,045 2012-02-15 0

SNODGRASS GERALD L VP, SALES

  • Officer
0 2009-11-10 0

PACIFIC COAST INVESTORS LTD

  • 10% Owner
No longer subject to file 2009-08-25 0

FLANDERS JOHN R V.P., GENERAL COUNSEL

  • Officer
32,500 2008-11-25 0

CHARTER VENTURES II, L.P.

CHARTER VENTURES

  • 10% Owner
No longer subject to file 2008-06-20 0

RITTER JOSEPH H EVP, GLOBAL BUS. OPERATIONS

  • Officer
0 2007-12-31 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT

2021-01-15 16:02:54 -0500 2021-01-14 F 1,666 $161.67 d 87,827 direct 1.3184 1.3184 2 0.0 1

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT

2021-01-15 16:02:54 -0500 2021-01-14 M 5,625 a 89,493 direct 1.3184 1.3184 2 0.0 1

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT

2021-01-15 16:02:54 -0500 2021-01-14 M 5,625 d 0 direct

HASENMAIER JOACHIM A. - Director

2021-01-12 17:07:20 -0500 2021-01-11 A 235 a 235 direct 6.1036 7.4424 9.4441 5 0.0 1

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT

2021-01-05 14:28:44 -0500 2020-12-31 F 1,194 $145.65 d 83,868 direct 5.133 2.3012 5.133 2 0.0 1

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT

2021-01-05 14:28:44 -0500 2020-12-31 A 4,119 a 85,062 direct 5.133 2.3012 5.133 2 0.0 1

WISNEWSKI NANCY - Officer CHIEF OPERATING OFFICER

2020-12-30 13:20:35 -0500 2020-12-28 M 6,000 $4.96 a 51,874 direct -0.7631 5.696 8.0125 5 -1.935 3

WISNEWSKI NANCY - Officer CHIEF OPERATING OFFICER

2020-12-30 13:20:35 -0500 2020-12-28 M 6,000 d 0 direct

WISNEWSKI NANCY - Officer CHIEF OPERATING OFFICER

2020-12-10 12:57:45 -0500 2020-12-09 S 200 $140.61 d 45,874 direct 1.6129 7.5556 7.5556 6 0.0 1

WISNEWSKI NANCY - Officer CHIEF OPERATING OFFICER

2020-12-10 12:57:45 -0500 2020-12-09 S 300 $140.23 d 46,074 direct 1.6129 7.5556 7.5556 6 0.0 1

WISNEWSKI NANCY - Officer CHIEF OPERATING OFFICER

2020-12-09 14:41:49 -0500 2020-12-08 S 150 $133.28 d 46,374 direct -0.5135 4.8424 4.8424 6 -0.5135 2

WISNEWSKI NANCY - Officer CHIEF OPERATING OFFICER

2020-12-09 14:41:49 -0500 2020-12-08 S 200 $133.03 d 46,524 direct -0.5135 4.8424 4.8424 6 -0.5135 2

WISNEWSKI NANCY - Officer CHIEF OPERATING OFFICER

2020-12-09 14:41:49 -0500 2020-12-07 S 150 $131.00 d 46,724 direct -0.5135 4.8424 4.8424 6 -0.5135 2

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT

2020-12-03 15:55:57 -0500 2020-12-01 M 5,625 d 5,625 direct

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT

2020-12-03 15:55:57 -0500 2020-12-01 F 1,631 $123.96 d 80,943 direct 2.2487 11.0632 30.659 30.659 31 0.0 1

WILSON KEVIN S. - Director - Officer CEO AND PRESIDENT

2020-12-03 15:55:57 -0500 2020-12-01 M 5,625 a 82,574 direct 2.2487 11.0632 30.659 30.659 31 0.0 1

AROESTY JASON D - Officer EVP, INTERNATIONAL DIAGNOSTICS

2020-11-30 15:56:22 -0500 2020-11-27 M 11,460 $106.67 a 11,460 direct -0.9842 12.3588 30.4211 30.4211 31 -0.9842 2

AROESTY JASON D - Officer EVP, INTERNATIONAL DIAGNOSTICS

2020-11-30 15:56:22 -0500 2020-11-27 M 11,460 d 5,729 direct

AROESTY JASON D - Officer EVP, INTERNATIONAL DIAGNOSTICS

2020-11-30 15:56:22 -0500 2020-11-27 S 10,233 $126.68 d 3,101 direct -0.9842 12.3588 30.4211 30.4211 31 -0.9842 2

AROESTY JASON D - Officer EVP, INTERNATIONAL DIAGNOSTICS

2020-11-30 15:56:22 -0500 2020-11-27 M 1,874 d 937 direct

AROESTY JASON D - Officer EVP, INTERNATIONAL DIAGNOSTICS

2020-11-30 15:56:22 -0500 2020-11-27 M 1,874 $106.67 a 13,334 direct -0.9842 12.3588 30.4211 30.4211 31 -0.9842 2

AROESTY JASON D - Officer EVP, INTERNATIONAL DIAGNOSTICS

2020-11-30 15:56:22 -0500 2020-11-27 S 3,101 $127.44 d 0 direct -0.9842 12.3588 30.4211 30.4211 31 -0.9842 2

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments